Literature DB >> 35759152

Accuracy and safety of 101 consecutives neurosurgical procedures for newly diagnosed central nervous system lymphomas: a single-institution experience.

Marc Zanello1,2, Johan Pallud3,4, Ilyes Aliouat1,2, Alessandro Moiraghi1,2, Giorgia Antonia Simboli1,2, Rudy Birsen5, Angela Elia1,2,6, Alexandre Roux1,2, Jérôme Tamburini5, Edouard Dezamis1, Eduardo Parraga1, Chiara Benevello1,2, Diane Damotte7, Corentin Provost2,8, Catherine Oppenheim2,8, Didier Bouscary5, Fabrice Chretien9.   

Abstract

INTRODUCTION: Brain surgery is required to ascertain the diagnosis of central nervous system lymphoma. We assessed the diagnostic yield and safety of the surgical procedures, the predictors of postoperative morbidity, and of overall survival.
METHODS: Observational single-institution retrospective cohort study (1992-2020) of 101 consecutive adult patients who underwent stereotactic biopsy, open biopsy, or resection for a newly diagnosed central nervous system lymphoma.
RESULTS: The diagnostic yield was 100% despite preoperative steroid administration in 48/101 cases (47.5%). A preoperative Karnofsky Performance Status score less than 70 (p = 0.006) was an independent predictor of a new postoperative focal neurological deficit (7/101 cases, 6.9%). A previous history of hematological malignancy (p = 0.049), age 65 years or more (p = 0.031), and new postoperative neurological deficit (p < 0.001) were independent predictors of a Karnofsky Performance Status score decrease 20 points or more postoperatively (13/101 cases, 12.9%). A previous history of hematological malignancy (p = 0.034), and preoperative Karnofsky Performance Status score less than 70 (p = 0.024) were independent predictors of postoperative hemorrhage (13/101 cases, 12.9%). A preoperative Karnofsky Performance Status score less than 70 (p = 0.019), and a previous history of hematological malignancy (p = 0.014) were independent predictors of death during hospital stay (8/101 cases, 7.9%). In the 82 immunocompetent patients harboring a primary central nervous system lymphoma, age 65 years or more (p = 0.044), and time to hematological treatment more than 21 days (p = 0.008), were independent predictors of a shorter overall survival. A dedicated hematological treatment (p < 0.001) was an independent predictor of a longer overall survival.
CONCLUSION: Brain biopsy is feasible with low morbidity for central nervous system lymphomas. Postoperatively, patients should be promptly referred for hematological treatment initiation.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Biopsy; Efficacy; Lymphoma; Safety; Steroid; Surgery

Mesh:

Year:  2022        PMID: 35759152     DOI: 10.1007/s11060-022-04069-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  21 in total

1.  Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study.

Authors:  R Velasco; S Mercadal; F Graus; N Vidal; M Alañá; M I Barceló; M J Ibáñez-Juliá; S Bobillo; R Caldú Agud; E García Molina; P Martínez; P Cacabelos; A Muntañola; G García-Catalán; J M Sancho; I Camro; T Lado; M E Erro; L Gómez-Vicente; A Salar; A C Caballero; M Solé-Rodríguez; J Gállego Pérez-Larraya; N Huertas; J Estela; M Barón; N Barbero-Bordallo; M Encuentra; I Dlouhy; J Bruna
Journal:  J Neurooncol       Date:  2020-06-10       Impact factor: 4.130

2.  Diagnostic delay in primary central nervous system lymphoma.

Authors:  Ingfrid S Haldorsen; Ansgar Espeland; John Ludvig Larsen; Olav Mella
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

Review 3.  Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology.

Authors:  Khê Hoang-Xuan; Eric Bessell; Jacoline Bromberg; Andreas F Hottinger; Matthias Preusser; Roberta Rudà; Uwe Schlegel; Tali Siegal; Carole Soussain; Ufuk Abacioglu; Nathalie Cassoux; Martina Deckert; Clemens M F Dirven; Andrés J M Ferreri; Francesc Graus; Roger Henriksson; Ulrich Herrlinger; Martin Taphoorn; Riccardo Soffietti; Michael Weller
Journal:  Lancet Oncol       Date:  2015-07       Impact factor: 41.316

4.  Robot-Assisted Stereotactic Biopsies in 377 Consecutive Adult Patients with Supratentorial Diffuse Gliomas: Diagnostic Yield, Safety, and Postoperative Outcomes.

Authors:  Marc Zanello; Alexandre Roux; Suhan Senova; Sophie Peeters; Myriam Edjlali; Arnault Tauziede-Espariat; Edouard Dezamis; Eduardo Parraga; Gilles Zah-Bi; Marc Harislur; Catherine Oppenheim; Xavier Sauvageon; Fabrice Chretien; Bertrand Devaux; Pascale Varlet; Johan Pallud
Journal:  World Neurosurg       Date:  2021-01-04       Impact factor: 2.104

5.  Hemorrhagic Attitude in Frameless and Frame-Based Stereotactic Biopsy for Deep-Seated Primary Central Nervous System Lymphomas in Immunocompetent Patients: A Multicentric Analysis of the Last Twenty Years.

Authors:  Giorgio Maria Callovini; Shahram Sherkat; Isabella Sperduti; Francesco Crispo; Laura Raus; Roberto Gazzeri; Stefano Telera
Journal:  World Neurosurg       Date:  2021-01-19       Impact factor: 2.104

6.  Complications after frame-based stereotactic brain biopsy: a systematic review.

Authors:  Maximilien Riche; Aymeric Amelot; Matthieu Peyre; Laurent Capelle; Alexandre Carpentier; Bertrand Mathon
Journal:  Neurosurg Rev       Date:  2020-01-04       Impact factor: 3.042

Review 7.  Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues.

Authors:  Kate E Grimm; Dennis P O'Malley
Journal:  Ann Diagn Pathol       Date:  2018-10-02       Impact factor: 2.090

8.  Age, gender, and racial differences in incidence and survival in primary CNS lymphoma.

Authors:  J L Villano; M Koshy; H Shaikh; T A Dolecek; B J McCarthy
Journal:  Br J Cancer       Date:  2011-09-13       Impact factor: 7.640

9.  Comparison of Frame-Based Versus Frameless Image-Guided Intracranial Stereotactic Brain Biopsy: A Retrospective Analysis of Safety and Efficacy.

Authors:  Lior Ungar; Ortal Nachum; Zion Zibly; Anton Wohl; Ran Harel; Moshe Attia; Roberto Spiegelmann; Jacob Zaubermann; Zeev Feldman; Nachshon Knoller; Zvi R Cohen
Journal:  World Neurosurg       Date:  2021-07-29       Impact factor: 2.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.